This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Walgreen May Launch Hostile Longs Bid

Walgreen (WAG) said it may take its bid to acquire Longs Drug Stores (LDG)directly to Longs shareholders if the pharmacy chain refuses to discuss a deal.

In a letter sent to the board of Longs on Monday, Walgreen disputed Longs' position that it's not willing to accept the regulatory risks in connection with an acquisition. Walgreen also said Longs should have no concern with its ability to finance the proposed transaction.

"Our proposal is compelling -- it would deliver superior value to Longs stockholders relative to the CVS transaction and can be consummated without undue delay," said the letter from Jeffrey Rein, Walgreen chairman and CEO.

In August, Longs agreed to sell itself to CVS Caremark (CVS - Get Report) for about $2.9 billion, or $71.50 a share. The offer carried a sizable premium, but because Longs controls a valuable real estate portfolio -- and hasn't gotten the portfolio appraised -- its shareholders felt shortchanged. As a result, CVS managed to secure just 4.5% of Longs' stock by the time its first tender offer expired.

Earlier this month, Walgreen offered to buy Longs for $75 a share, and also agreed to cover a breakup fee, equal to another $3 a share, if Longs would accept its proposal. But Longs has rebuffed the offer from Walgreen.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,362.77 -54.08 -0.31%
S&P 500 2,009.93 -11.32 -0.56%
NASDAQ 4,677.9730 -5.4340 -0.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs